ens16’ CAGR
incl. nemolizumab



+15-17%
CC CAGR









Injectable Aesthetics



‘Low to mid-teens16’ CAGR



+10-12%

CC CAGR









Dermatological Skincare



‘High single- to low-teens16’ CAGR



+8.5-10.5%

CC CAGR









Therapeutic Dermatology



‘High-teens16’ CAGR
incl. nemolizumab



>30%

CC CAGR





Pro
=*=*=*=*=*=
当前为第44/55页
下一页-上一页-
=*=*=*=*=*=
返回新闻列表
返回网站首页